*Licence Name/Nom de l'homologation: Application Number/Numéro di 315999 Licence # / # de l'homologation: Application Type/Type de soum 0 Interim Order Manufacturer/Fabricant: Company ID/Identificateur d'en HYRIS LTD 156034 Risk Class: Rationale: 3 Classification Rule IVDD *Licence Type/Type d'homologation: Rationale: *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications Contains Controlled Substance(s) Contains Controlled Substance(s) Contains Drug(s) Contains The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal sw from patients suspected of	n
Licence # / # de l'homologation: Application Type/Type de soum 0 Interim Order Manufacturer/Fabricant: Company ID/Identificateur d'en HYRIS LTD 156034 Risk Class: Rationale: 3 Classification Rule IVDD *Licence Type/Type d'homologation: Rationale: Test Kit Image: Contains Controlled Substance(s) Contains Drug(s) Contains *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swafrom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decisis Positive test results indicate the presence of SARS-CoV-Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective inf assess if that is the effective cause of the patient's disear In any case report all positive results to the appropriate provision of the patient's disear In any case report all positive results to the appropriate protent provision of the patient's disear In an	oumission
0 Interim Order Manufacturer/Fabricant: Company ID/Identificateur d'en HYRIS LTD 156034 Risk Class: Rationale: 3 Classification Rule IVDD *Licence Type/Type d'homologation: Rationale: Test Kit Rationale: Contains Controlled Substance(s) Contains Drug(s) *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swafrom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decision Positive test results indicate the presence of SARS-CoV-Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective inf <td< th=""><th></th></td<>	
Manufacturer/Fabricant: Company ID/Identificateur d'en 156034 Risk Class: Rationale: 3 Classification Rule IVDD I *Licence Type/Type d'homologation: Rationale: Test Kit Image: Rationale: Contains Controlled Substance(s) Contains Drug(s) *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swafrom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decisis Positive test results indicate the presence of SARS-CoV-Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective infasses if that is the effective cause of the patient's disear In any case report all positive results to the appropriate provide test results indicate the presence of the patient's disear In any case report all positive results to the appropriate provide test results in the effective cause of the patient's disear In any case report all positive results to the appropriate provide test results in the fifective cause of the patient's disear In any case rep	ion:
HYRIS LTD 156034 Risk Class: Rationale: 3 Classification Rule IVDD *Licence Type/Type d'homologation: Rationale: Test Kit Rationale: Contains Controlled Substance(s) Contains Drug(s) *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swafrom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decision Positive test results indicate the presence of SARS-CoV-Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patient clinical information in order to determine the effective infasses if that is the effective cause of the patient's diseare in any case report all positive results to the appropriate provide the presence of the patient's diseare in any case report all positive results to the appropriate provide the provide test results in the detection from the patient's diseare in any case report all positive results to the appropriate provide testerest cause of the p	
Risk Class: Rationale: 3 Classification Rule IVDD *Licence Type/Type d'homologation: Rationale: Test Kit Rationale: Contains Controlled Substance(s) Contains Drug(s) Contains Controlled Substance(s) Contains Drug(s) *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swaftom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decisis Positive test results indicate the presence of SARS-CoV-2 Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective infasses if that is the effective cause of the patient's disea In any case report all positive results t	eprise:
3 Classification Rule IVDD *Licence Type/Type d'homologation: Rationale: Test Kit Image: Rationale: Contains Controlled Substance(s) Contains Drug(s) Contains Controlled Substance(s) Contains Drug(s) *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swafrom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decisis Positive test results indicate the presence of SARS-CoV-Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective inf assess if that is the effective cause of the patient's diseare in any case report all positive results to the appropriate provide the presence of the patient's diseare in any case report all positive results to the appropriate provide the presence of the patient's diseare in any case report all positive results to the appropriate provide the presence of the patient's diseare in any case report all positive results to the appropriate provide the presence of the patient's diseare in any case report all positive results to the appropriate provide the presen	
*Licence Type/Type d'homologation: Test Kit Contains Controlled Substance(s) Contains Drug(s) Contains Contains Controlled Substance(s) Contains Drug(s) Contains The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detectio nucleic acid in nasopharyngeal swabs (NPS) or nasal swa from patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decisie Positive test results indicate the presence of SARS-CoV- Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective inf assess if that is the effective cause of the patient's disear In any case report all positive results to the appropriate p	ulo 2/b)/i)
Test Kit Contains Controlled Substance(s) Contains Drug(s) Contains *Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications Contains The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swafrom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decision Positive test results indicate the presence of SARS-CoV-Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective infasses if that is the effective cause of the patient's diseare in any case report all positive results to the appropriate prime of the patient's diseare in any case report all positive results to the appropriate patient in the patient in the presence of the patient's diseare in any case report all positive results to the appropriate patient is the patient in the patient's diseare in any case report all positive results to the appropriate patient is the patient in the patient's diseare in any case report all positive results to the appropriate patient in the patient is the patient's diseare in any case report all positive results to the appropriate patient is the patient in the patient is	ile 2(b)(l)
Contains Controlled Substance(s) Contains Drug(s) Contains The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swafrom patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specinacute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decision Positive test results indicate the presence of SARS-CoV-Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patient in assess if that is the effective cause of the patient's disease.	
*Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detectio nucleic acid in nasopharyngeal swabs (NPS) or nasal swa from patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decisio Positive test results indicate the presence of SARS-CoV- Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective inf assess if that is the effective cause of the patient's disear In any case report all positive results to the appropriate p	
The bKIT Virus Finder COVID-19 real-time RT-PCR assay the bCUBE instrument for the in vitro qualitative detectio nucleic acid in nasopharyngeal swabs (NPS) or nasal sw from patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decisie Positive test results indicate the presence of SARS-CoV- Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patie clinical information in order to determine the effective inf assess if that is the effective cause of the patient's disea In any case report all positive results to the appropriate p	ns Biological Material(s)
the bCUBE instrument for the in vitro qualitative detection nucleic acid in nasopharyngeal swabs (NPS) or nasal swa from patients suspected of COVID-19 disease. The assay is meant for the detection of SARS-CoV-2 RNA present in detectable quantity in upper respiratory specin acute phase of the disease. This test is an aid in the diagnosis of COVID-19 disease. do not exclude SARS-CoV-2 infection and must be comb data including epidemiological information, patient histo observations in order to take patient management decision Positive test results indicate the presence of SARS-CoV- Co-existence of infection from other viruses or bacterias The test outcome should be evaluated together with patient clinical information in order to determine the effective infl assess if that is the effective cause of the patient's disear In any case report all positive results to the appropriate p	
The bKIT Virus Finder COVID-19 is intended for point-of- specifically instructed and trained in the use of this device bCUBE instrument. bKIT Virus Finder COVID-19 is a med for a clinical trial in respect of a COVID-19 medical device under the Interim Order Respect in Clinical Trials for Med Drugs Relating to COVID-19 (Interim Order).	of SARSCoV-2 bs (NS) specimens which is generally ens during the egative test results ned with additional y and clinical ns. RNA in the sample. can't be excluded. In thistory and other ction status and to e. ublic health are use by personnel and of the cal device purposed as authorized

OEM Licence	Information
OEM Licence Name :	OEM Manufacturer :
OEM Intended Use and/or Indications for Use	

Reason for Change	Comment(s)
Change to classification of a device	
Manufacturer name change	
License name change	
Device name change	
Change to the purpose/indication of	



license	
Addition of device(s)	
Deletion of device(s)	

Reason for Change	Comment(s)
Change in name and/or address of the	
Private Label Manufacturer	
Private Label License name change	
Private Label Device name change	
Addition of device(s)	
Deletion of device(s)	

Certificate Screening Checklist:

Cert Revisions / Comments (If Applicable):

Criteria	conforms	Comments/info for MDS
Issued to full name of manufacturer as it appears		
on application/licence and label.		
Issued to complete civic address matching		
application/licence and label.		
Criteria are ISO 13485:2016 and Medical Devices		
Regulations – Part 1 – SOR 98/282		
Scope activities limited to design, development,		
manufacture, production, servicing, installation,		
or distribution.		
Activities include "manufacture" or "production"		
Activities include "design" or "development and		
development" for class III/IV devices.		
Scope is unambiguous and covers app./lic.		
devices. Does not contain product		
names/models/licence numbers.		
Auditing Organisation is Authorized or		
Recognized		
Statement of Authorization or Recognition.		
Field labelled "Effective Date"		
Field labelled "Expiry Date"		
Validity period ≤ 3 years		
Unique identification code labelled "certificate		🗆 new 🛛 revised
number" or "certification document number"		🗆 new 🛛 revised
Name, title, and signature of certification		
authority		
Pagination (page x or y) included on all pages . All		
pages present.		



Method to verify validity			
Screen	ing Decision		
Accept		•	·
Jiazhen Minnie Dai		Date:2020-06-11	
Device Licensing Services Division Medical Devices Bureau			



Check GMDN

GMDN Name	GMDN	GMDN Description	lssue	Action for Screener	Regulatory Action	Reference Material
	Code					